• Racura Oncology cleared to escalate RC220 dosing in the Phase 1 HARNESS-1 trial combining RC220 with AstraZeneca’s osimertinib in EGFR-mutant NSCLC.
• The safety review found no dose-limiting toxicities or treatment-related safety concerns in the initial low-dose cohort.
• The study will now enroll the next cohort at a higher dose; clinical activity results were not presented in this update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Racura Oncology Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610120700PR_NEWS_USPR_____CN69645) on October 12, 2026, and is solely responsible for the information contained therein.